475086-75-0

Basic information

• Product Name: SELEXIPAG interMediate
• Synonyms: SELEXIPAG interMediate;4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol;Selexipag intermediates;1-Butanol, 4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]-;1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-;4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]-1-butanol;-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol;4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butan-1-ol
• CAS NO: 475086-75-0
• Molecular Formula: C₂₃H₂₇N₃O
• Molecular Weight: 361.47998
• EINECS: 1592732-453-0
• Product Categories: non-prostanoid prostacyclin (PGI2) receptor agonist
• Mol File: 475086-75-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 514.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.112±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: SELEXIPAG interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: SELEXIPAG interMediate(475086-75-0)
• EPA Substance Registry System: SELEXIPAG interMediate(475086-75-0)

Safety Data

• Hazardous Substances Data: 475086-75-0(Hazardous Substances Data)

Usage

Uses

4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-butanol is a diphenylpyrazine derivative which belongs to a class of prostacyclin receptor agonists. It is an impurity of Selexipag (S253150) that is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.

Upstream product

• 41270-66-0 2-chloro-5,6-diphenylpyrazine 
• 42042-71-7 4-hydroxy-N-isopropylbutan-1-amine 
• 243472-70-0 2-bromo-5,6-diphenylpyrazine 
• 928-51-8 4-Chloro-1-butanol 
• 18591-57-6 5,6-diphenyl-2-hydroxypyrazine 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 18591-57-6 2,3-Diphenyl-6-hydroxypyrazine 
• 101727-15-5 2-iodo-5,6,-diphenylpyrazine 
• 39099-23-5 N-isopropyl-N-butylamine 
• 447-31-4 Desyl chloride 

Downstream Products

• 475084-96-9 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butyl ester 
• 475086-01-2 Selexipag 

Relevant articles and documents

Synthesis method of selexipag intermediate

The invention relates to the technical field of medicine synthesis, in particular to a synthesis method of a selexipag intermediate. The preparation method comprises the following steps: reacting a compound as shown in a formula III with 2-aminoacetamidine hydrobromide under the action of a catalyst to obtain a compound as shown in a formula IV; reacting the compound as shown in the formula IV with 4-bromo-1-butanol under the action of alkali to obtain a compound as shown in a formula V; and carrying out N-alkylation reaction on the compound as shown in the formula V under the action of alkali to obtain the selexipag intermediate as shown in the formula I: 4-[(5, 6-diphenylpyrazine-2-yl) (isopropyl alcohol group) amino]-1-butanol. The invention creates a novel synthesis method of the selexipag intermediate, and the method has the advantages of cheap and easily available raw materials, simple operation, mild conditions and high yield.

High yield preparation method of selexipag intermediate compound under middle conditions

The invention relates to a high yield preparation method of a selexipag intermediate compound under middle conditions. According to the method, styracitol and halogen acid carry out halogenation reactions, and the reaction product and N-aminoacetyl-N-isopropyl n-butanol carry out condensation, ammoxidation, and ring forming reactions to obtain 2-(N-isopropyl-N-4-hydroxylbutyl)amino-5,6-diphenylpyrazine. The compound can be used to prepare selexipag. The raw materials are cheap and easily available, the operation is simple, convenient and safe, the reaction selectivity is good, the yield and purity are high, and the cost is low.

INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME

Disclosed herein are small molecule inhibitors of platelet function, and methods of using the small molecules to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.